#152086

MCF7/TAMR-8 Cell Line

Please Enter Your Email ID
Email ID

Cat. #152086

MCF7/TAMR-8 Cell Line

Cat. #: 152086

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-5 days

Organism: Human

Tissue: Breast

Disease: Cancer

Model: Tumour line

£800.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne Lykkesfeldt

Institute: Danish Cancer Society

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: MCF7/TAMR-8 Cell Line
  • Alternate name: MCF-7/TAMR-8; TAMR-8
  • Cancer: Breast cancer
  • Cancers detailed: Breast cancer;Tamoxifen resistant
  • Research fields: Cancer;Drug development
  • Tool sub type: Continuous
  • Parental cell: MCF7 S0.5
  • Organism: Human
  • Gender: Female
  • Tissue: Breast
  • Disease: Cancer
  • Model: Tumour line
  • Conditional: Yes
  • Description: MCF7/TAMR-8 cell line is a stable tamoxifen-resistant subline. This cell line has been established in tissue culture after long term treatment with 1 uM tamoxifen. Tamoxifen (Nolvadex) is a widely used drug for hormone-dependent cancer. Tamoxifen resistance (either primary or acquired) makes oestrogen receptor-positive breast cancer much more difficult to treat. This cell line was produced from the parental cell line MCF7/S0.5, as a model cell system to study the effects of tamoxifen resistant cancer growth. Tamoxifen-resistant cells are passaged continuously in the presence of 1 uM tamoxifen. This concentration is lethal for the parental cell line. MCF7/TAMR-8 cells are oestrogen receptor positive and progesterone receptor negative. Previous applications of this cell line include treatment with steroidal antioestrogens. MCF7/TAMR-8 enables identification of new hormone therapies and greater understanding of the signalling pathways/methods behind tamoxifen resistance. Additionally MCF/TAMR-8 can aid in identifying new predictive markers for response to hormonal therapy.
  • Application: Investigate signalling pathways involved in tamoxifen
  • Production details: The parental cell line for the MCF7/TAMR-8 cells is MCF7/S0.5, which was adapted to grow at low serum concentration in order to study the effect of estradiol and tamoxifen. MCF7/TAMR-8 has been established from a clone of cells that survived long term treatment with 1 uM tamoxifen. Tamoxifen-resistant cells are passaged continuously in presence of 1 uM tamoxifen, which is lethal for the parental MCF7/S0.5 cell line.
  • Biosafety level: 1
  • Additional notes: MCF7/TAMR-8 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-8 cells are growth inhibited by the pure antioestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-8 cell.
  • Recommended controls: MCF7-S0.5 parental line
  • Cellosaurus id: CVCL_1D44

Target Details

  • Target: Oestrogen receptor

Applications

  • Application: Investigate signalling pathways involved in tamoxifen
  • Application notes: MCF7/TAMR-8 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-8 cells are growth inhibited by the pure antioestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-8 cell. Passage 398 (AL2687, AL2688)

Handling

  • Format: Frozen
  • Passage number: Passage 398 (AL2687, AL2688)
  • Growth medium: Phenol red-free DMEM:Ham's F-12 containing 1% fetal bovine serum, 2 mM Glutamax and 6 ng/ml insulin. To maintain high-level resistance, medium was supplemented with Tamoxifen (1 uM).
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

Related Tools

  • Related tools: MCF7/S0.5 Cell Line

References

  • Thrane et al. 2015. Oncogene. 34(32):4199-210. PMID: 25362855.
  • Elias et al. 2015. Oncogene. 34(15):1919-1927. PMID: 24882577.
  • Pedersen et al. 2014. Int J Oncol. 45(5):2167-2175. PMID: 25175082.
  • Lundqvist et al. 2014. Steroids. 85:30-35. PMID: 24747771.
  • Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.
  • Larsen et al. 2012. Int J Oncol. 41(5):1863-1870. PMID: 22961366.
  • Cutrupi et al. 2012. Oncogene. 31(40):4353-4361. PMID: 22249258.
  • Frankel et al. 2007. Bre...